Skip to main content

Main menu

  • Home
  • Content
    • First Release
    • Current
    • Archives
    • Collections
    • Audiovisual Rheum
    • COVID-19 and Rheumatology
  • Resources
    • Guide for Authors
    • Submit Manuscript
    • Payment
    • Reviewers
    • Advertisers
    • Classified Ads
    • Reprints and Translations
    • Permissions
    • Meetings
    • FAQ
    • Policies
  • Subscribers
    • Subscription Information
    • Purchase Subscription
    • Your Account
    • Terms and Conditions
  • About Us
    • About Us
    • Editorial Board
    • Letter from the Editor
    • Duncan A. Gordon Award
    • Privacy/GDPR Policy
    • Accessibility
  • Contact Us
  • JRheum Supplements
  • Services

User menu

  • My Cart
  • Log In
  • Log Out

Search

  • Advanced search
The Journal of Rheumatology
  • JRheum Supplements
  • Services
  • My Cart
  • Log In
  • Log Out
The Journal of Rheumatology

Advanced Search

  • Home
  • Content
    • First Release
    • Current
    • Archives
    • Collections
    • Audiovisual Rheum
    • COVID-19 and Rheumatology
  • Resources
    • Guide for Authors
    • Submit Manuscript
    • Payment
    • Reviewers
    • Advertisers
    • Classified Ads
    • Reprints and Translations
    • Permissions
    • Meetings
    • FAQ
    • Policies
  • Subscribers
    • Subscription Information
    • Purchase Subscription
    • Your Account
    • Terms and Conditions
  • About Us
    • About Us
    • Editorial Board
    • Letter from the Editor
    • Duncan A. Gordon Award
    • Privacy/GDPR Policy
    • Accessibility
  • Contact Us
  • Follow jrheum on Twitter
  • Visit jrheum on Facebook
  • Follow jrheum on LinkedIn
  • Follow jrheum on YouTube
  • Follow jrheum on Instagram
  • Follow jrheum on RSS
Research ArticleArticle

Adipose Depots, Not Disease-related Factors, Account for Skeletal Muscle Insulin Sensitivity in Established and Treated Rheumatoid Arthritis

Hiba AbouAssi, K. Noelle Tune, Brian Gilmore, Lori A. Bateman, Gary McDaniel, Michael Muehlbauer, Janet L. Huebner, Helen M. Hoenig, Virginia B. Kraus, E. William St. Clair, William E. Kraus and Kim M. Huffman
The Journal of Rheumatology October 2014, 41 (10) 1974-1979; DOI: https://doi.org/10.3899/jrheum.140224
Hiba AbouAssi
From the Divisions of Endocrinology, Rheumatology and Immunology, Cardiology, Geriatrics, Department of Medicine and Duke Molecular Physiology Institute, Duke University Medical Center; Durham Veterans Affairs Medical Center, Durham, North Carolina, USA.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
K. Noelle Tune
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Brian Gilmore
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lori A. Bateman
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gary McDaniel
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Michael Muehlbauer
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Janet L. Huebner
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Helen M. Hoenig
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Virginia B. Kraus
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
E. William St. Clair
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
William E. Kraus
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kim M. Huffman
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: kim.huffman@duke.edu
  • Article
  • Figures & Data
  • References
  • Info & Metrics
  • PDF
  • eLetters
PreviousNext
Loading

Abstract

Objective. In prior reports, individuals with rheumatoid arthritis (RA) exhibited increased insulin resistance. However, those studies were limited by either suboptimal assessment methods for insulin sensitivity or a failure to account for important determinants such as adiposity and lack of physical activity. Our objectives were to carefully assess, compare, and determine predictors of skeletal muscle insulin sensitivity in RA, accounting for adiposity and physical activity.

Methods. Thirty-nine individuals with established (seropositive or erosions) and treated RA and 39 controls matched for age, sex, race, body mass index, and physical activity underwent a frequently sampled intravenous glucose tolerance test to determine insulin sensitivity. Inflammation, body composition, and physical activity were assessed with systemic cytokine measurements, computed tomography scans, and accelerometry, respectively. Exclusions were diabetes, cardiovascular disease, medication changes within 3 months, and prednisone use over 5 mg/day. This investigation was powered to detect a clinically significant, moderate effect size for insulin sensitivity difference.

Results. Despite elevated systemic inflammation [interleukin (IL)-6, IL-18, tumor necrosis factor-α; p < 0.05 for all], persons with RA were not less insulin sensitive [SI geometric mean (SD): RA 4.0 (2.4) vs control 4.9 (2.1)*10−5 min−1/(pmol/l); p = 0.39]. Except for visceral adiposity being slightly greater in controls (p = 0.03), there were no differences in body composition or physical activity. Lower insulin sensitivity was independently associated with increased abdominal and thigh adiposity, but not with cytokines, disease activity, duration, disability, or disease-modifying medication use.

Conclusion. In established and treated RA, traditional risk factors, specifically excess adiposity, play more of a role in predicting skeletal muscle insulin sensitivity than do systemic inflammation or other disease-related factors.

Key Indexing Terms:
  • SKELETAL MUSCLE
  • INSULIN RESISTANCE
  • PHYSICAL ACTIVITY
  • BODY COMPOSITION

In persons with rheumatoid arthritis (RA), 2-fold increased rates of cardiovascular (CV) disease have been attributed, in part, to insulin resistance1,2. Potential explanations for insulin resistance in RA have included higher systemic inflammation associated with active disease, use of glucocorticoids, and increased traditional risks such as abdominal obesity and inactivity2,3.

Most prior investigations of insulin resistance in RA have relied largely on fasting measures that better reflect hepatic rather than skeletal muscle insulin sensitivity. Assessing insulin sensitivity is critical, because skeletal muscle is responsible for as much as 90% of glucose uptake after a meal. Further, skeletal muscle insulin resistance initiates and perpetuates the development of type 2 diabetes and serves as the central feature of the metabolic syndrome4,5. Of the few investigations in patients with RA that have used glucose challenge-based measures of insulin sensitivity, none have accounted for potential differences in adiposity and physical activity6,7,8,9,10. To improve understanding of how insulin resistance might contribute to increased CV risk in persons with RA, our objectives were to determine (1) whether persons with RA, as compared to controls matched for age, sex, race, body mass index (BMI), and physical activity, exhibit more skeletal muscle insulin resistance as assessed by intravenous (IV) glucose tolerance tests (IVGTT), and (2) in persons with RA, whether disease-specific and/or traditional predictors are related to skeletal muscle insulin resistance.

MATERIALS AND METHODS

Patient population

In this cross-sectional investigation, persons were included if they had (1) RA that met American College of Rheumatology 1987 criteria11, (2) seropositive disease (positive rheumatoid factor or anticyclic citrullinated peptide) or evidence of erosions, and (3) no medication changes within the 3 months prior to study enrollment. Persons using prednisone 5 mg or less daily were included. Any prednisone taper must have been completed at least 3 weeks prior to enrollment. Healthy individuals without a diagnosis of RA or joint pain or swelling lasting more than a week were matched to an RA participant by sex, race, age (within 3 yrs), and BMI (within 3 kg/m2). For 1 African American participant where a race match was not identified, a white person who was otherwise well-matched was included. Exclusion criteria were a history of diabetes or CV disease, current pregnancy, and use of medications known to affect carbohydrate or lipid metabolism (including insulin, oral antidiabetic agents, statins, fibrates, nicotinic acid, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, or β blockers). Participants with RA were recruited from Duke University and Durham Veterans Affairs Medical Center Rheumatology Clinics and from the local community with newspaper and website advertisements. Controls were recruited from the local community with newspaper and Website advertisements. Our study was in compliance with the Helsinki Declaration and was approved by the Duke University Institutional Review Board. All participants gave written informed consent.

Questionnaires and physical examination

Participants completed questionnaires for medications, disability (Health Assessment Questionnaire Disability Index)12, comorbidities13, a visual analog scale for health rating, and the Stanford Brief Activity Survey for physical activity14. Each completed a visual analog scale (VAS) for health, and underwent anthropometric measures, a 28-joint examination, and fasting blood collection for glucose, insulin, and erythrocyte sedimentation rate (ESR). The VAS, joint examination, and ESR were used to compute a Disease Activity Score (DAS28)15.

Accelerometry

Participants wore an RT3 tri-axial accelerometer (Stayhealthy Inc.) for 7 days. Data were obtained from accelerometers as activity calories per min (Stayhealthy RT3 Assist Version 1.0.6). Ninety consecutive min of no measured activity was used to indicate and eliminate periods of time when individuals were not wearing the device. Also, if there were fewer than 10 h of measured activity in a single day, all data from that day were excluded from analysis. Similarly, we excluded data from participants (n = 7) who had fewer than 4 days of valid data (each of 10 h or more of wear time). Two participants did not return the device.

Systemic inflammatory measures

A panel of proinflammatory cytokines including interleukin (IL)-1β, IL-6, IL-8, and tumor necrosis factor (TNF)-α were measured in plasma samples using a multiarray quantitative immunoassay (Meso Scale Discovery). IL-18 and high-sensitivity C-reactive protein (hsCRP) were measured using sandwich ELISA (R&D, and MP Biomedicals, respectively). Mean intraassay (within plate) coefficients of variation were as follows: IL-1β 9.3%, IL-6 3.4%, IL-8 3.9%, TNF-α 2.9%, IL-18 2.4%, and hsCRP 3.5%. A human plasma control was run on each plate, and mean interassay (between plates) coefficients of variation were as follows: IL-1β 5.5%, IL-6 3.0%, IL-8 7.8%, TNF-α 7.7%, IL-18 6.0%, and hsCRP 3.9%.

Insulin sensitivity and fatty acids

Insulin sensitivity was determined using a frequently sampled IVGTT. Glucose (50%) was injected through a catheter at 0.3 g/kg body mass. Insulin was injected at min 20 at 0.025 units/kg body mass. Twenty-nine blood samples were obtained over 3 hours, centrifuged, and stored at −80°C. Glucose was measured on a Beckman-CoulterDxC600 analyzer, and insulin by electrochemiluminescent assay from Meso Scale Discovery. Insulin sensitivity index was calculated using Bergman’s minimal model16. Nonesterified free fatty acids (NEFA) were measured by colorimetric enzymatic assay using a Beckman-Coulter DxC600 analyzer, with reagents from Wako.

Abdomen and thigh computerized tomography (CT) scans

Single 10-mm-thick axial sections at the liver and mid-thigh were performed using a General Electric CT/I scanner (GE Medical Systems). Cross-sectional areas for adipose tissue depots and liver and muscle density were measured using OsiriX (Pixmeo). CT scan determinations of adipose tissue depots are very accurate, precise, and reliable17,18.

Statistical analyses

Cytokines, NEFA, and insulin sensitivity index were logarithmically transformed prior to group comparisons. Comparisons between patients with RA and controls were performed with mixed models, which accounted for the repeated measure of matched participants. Bivariate associations were assessed with Spearman correlations. Multivariable modeling for insulin sensitivity index (log) was performed using linear models with backward stepwise variable selection. Initial variable inclusion was based on conceptual hypotheses regarding traditional risk factors and disease-associated factors affecting insulin sensitivity index and included age, sex, waist circumference, physical activity, disease activity (DAS28), disease-modifying agent use, biologic agent use, and prednisone use. Waist circumference was selected rather than BMI based on the high levels of correlation between the 2 (r = 0.87) and because waist circumference was more strongly correlated with insulin sensitivity index. For the laboratory model (based on results from bivariate analyses), visceral adiposity and thigh intermuscular adiposity were included rather than waist circumference, and IL-6 was included rather than disease activity; all other variables from the clinical model were included.

Statistical power

Our investigation was designed to detect a difference in insulin sensitivity that corresponded to a moderate effect size (0.4–0.5)19. Based on 39 matched pairs and an α of 0.05, we had 80% power to detect a standardized difference in insulin sensitivity index of 0.46.

RESULTS

Patients with RA were well matched to controls in age, sex, and BMI (Table 1). While patients with RA had slightly less abdominal visceral adiposity (p = 0.03), otherwise there were similar amounts of fasting NEFA, abdominal and thigh adipose tissue depots, and thigh muscle area and density (p > 0.05 for all). There were no differences in physical activity, measured as total energy expended (p > 0.05). In the context of a wide range of disease activity (DAS28 0.78–6.4) and duration (5–506 mos), individuals with RA exhibited a proinflammatory profile, as demonstrated by elevated TNF-α, IL-6, and IL-18 (p < 0.05 for all). Despite elevated systemic inflammation, persons with RA were not significantly less insulin-sensitive than controls [insulin sensitivity index (SI) geometric mean (SD) = 4.0 (2.4) vs 4.9 (2.0)*10−5 min−1/(pmol/l); mean SD for log SI = 0.23; p = 0.39].

View this table:
  • View inline
  • View popup
Table 1.

Participant characteristics. Data are presented as means (SD) for continuous variables and number (%) of participants for dichotomous variables. Data that were not normally distributed (systemic inflammatory markers, cytokines, and insulin sensitivity) are presented as geometric means (SD).

Table 2 shows correlations of key traditional and disease-specific risks with insulin sensitivity. In persons with RA, lower insulin sensitivity index was associated with a larger BMI (r = −0.45, p < 0.002), a greater waist circumference (r = −0.47, p < 0.001), and increased amounts of total abdominal adipose tissue, visceral adiposity, total thigh area, thigh intermuscular adiposity, and thigh muscle area (r = −0.3 to 0.5, p < −0.05 for all).

View this table:
  • View inline
  • View popup
Table 2.

Spearman correlations for insulin sensitivity, n = 44.

Multivariable modeling was performed using variables available in a clinic setting: age, sex, waist circumference, physical activity, disease activity, biologic use, use of disease-modifying antirheumatic drugs, and prednisone use. After backward variable selection, the model retained only waist circumference and accounted for 26% of the variance in insulin sensitivity index (Table 3, p < 0.0005). To better understand the contribution of inflammation and adiposity, a “laboratory” model was constructed. For this model, initial variables included visceral adiposity and thigh intermuscular adiposity rather than waist circumference, IL-6 rather than disease activity, and all of the other variables in the initial clinical model. In the laboratory model, visceral adiposity, thigh intermuscular adiposity, and IL-6 accounted for 46% of the variance in insulin sensitivity index (Table 3; p < 0.0005). Visceral adiposity (p < 0.005) and thigh intermuscular adiposity (p < 0.02) were each independently related to insulin sensitivity index.

View this table:
  • View inline
  • View popup
Table 3.

Multivariable model for insulin sensitivity index (log) in persons with rheumatoid arthritis.

DISCUSSION

In 39 persons with established RA (well controlled and reflective of many clinic cohorts), insulin sensitivity index, as measured with an IVGTT, was not significantly lower than in matched controls. Also, for persons with RA, insulin sensitivity was related to traditional risk factors of large adipose tissue depots. Other than concentrations of IL-6, disease-specific factors, including disease activity, biologic agent use, and disease-modifying agent use had little apparent influence on this outcome.

To our knowledge, this is the first well-controlled comparison of insulin sensitivity index for persons with established and treated RA. Previously, most studies addressing insulin sensitivity in RA used fasting glucose-derived and insulin-derived indices such as homeostasis model assessment and the quantitative insulin sensitivity check index2; however, those fasting-derived indices reflect insulin sensitivity mainly in the liver. In contrast, glucose tolerance tests better reflect insulin sensitivity in skeletal muscle. Because skeletal muscle is responsible for the majority (up to 90%) of systemic glucose uptake after a glucose load such as during a meal, assessing insulin sensitivity index with glucose challenge tests is critical for understanding insulin action.

Despite the importance outlined above, glucose challenge tests, including oral and IV glucose loads as well as euglycemic clamps, have been used to compare insulin sensitivity between RA and controls in a relatively small number of investigations6,7,8,9,10,20. Findings from these have been conflicting, likely because of a failure to adequately assess and account for the significant contributors to insulin resistance, adiposity, and physical inactivity. Specifically, several investigations demonstrated that persons with untreated RA had greater insulin resistance, but none included BMI-matched controls or assessed physical activity8,9,20. Also, in 2 investigations, persons with RA had insulin sensitivity similar to that of controls, but in one, the comparison was confounded by the control group having more males and higher BMI6. The second investigation was limited to normal weight, premenopausal females, limiting generalizability. Our study shows definitively that despite elevated amounts of systemic inflammation when compared to controls matched for adiposity and physical inactivity, persons with RA have similar insulin sensitivity.

Thus, in typical clinical cohorts of established and well-controlled RA, the average reduction in insulin sensitivity index imposed by RA-associated factors appears both statistically and clinically insignificant. Statistical power for this investigation aimed to detect a difference in insulin sensitivity corresponding to a moderate effect size, so the observed small difference was not statistically significant. Clearly, a larger sample might have been able to detect the small difference as statistically significant, but the critical issue is the clinical relevance of such a small difference in insulin sensitivity.

Clinical relevance for specific insulin sensitivity values is difficult to determine, but some investigations linking insulin sensitivities to outcomes can provide insight into this issue. When persons were followed longitudinally for 25 years for diabetes development, the difference was much larger than ours between those who developed type 2 diabetes and those who did not [3.2 ± 2.4 vs 8.1 ± 6.7 10−5 min−1/(pmol/l)]21. Also, when comparing tertiles of insulin sensitivity, the upper tertile (≥ 2.39*10−5 min−1 /[pmol/l]) was associated with an incidence of progression of < 10%22. This low incidence suggests that the effect of the small difference observed between persons with well-controlled RA and matched controls is clinically negligible.

As a means of confirming that risk of insulin sensitivity in well-controlled RA is similar to that of matched controls, we observed that predictors of insulin sensitivity in RA are largely traditional cardiometabolic risk factors rather than RA-specific ones. Prior predictors of RA-associated insulin resistance include both altered body composition and inflammation2,3,6,9. Covering a wide range of insulin sensitivities and disease activities, our sample provided a rich source to identify potential unique mediators of insulin resistance development in persons with RA. Nonetheless, except for IL-6 concentrations, all correlates of insulin sensitivity were to body composition. These findings imply that in persons with established and treated RA, traditional risk factors, specifically excess adiposity, play more of a role in predicting insulin sensitivity index than do inflammation or medication use.

A wide range of hypotheses and evidence link adipose tissue and skeletal muscle insulin resistance. Adipose tissue contributes to skeletal muscle insulin resistance by providing a source of free fatty acids, which inhibit insulin-stimulated glucose uptake in skeletal muscle both directly and indirectly (by promoting production of acyl-CoA and reactive oxygen species)23. Additionally, adipose tissue triggers skeletal muscle insulin resistance through the production of a number of insulin resistance-promoting inflammatory cytokines and adipokines24.

While adipose tissue clearly contributed, skeletal muscle insulin resistance in RA appeared to have little relation to disease-specific factors. Of these, only IL-6 was related. Specifically, higher IL-6 was related to poorer insulin sensitivity, with a p value of 0.05 in bivariate analyses and a trend toward statistical significance in a multivariable model. In persons without systemic inflammatory disease, IL-6 has shown a complex relationship with insulin sensitivity25. Acutely, increases in IL-6 associated with exercise have been shown to improve insulin sensitivity, but chronic elevations appear to worsen insulin sensitivity25. Here, in persons with elevated systemic concentrations of IL-6, this cytokine was related to poorer insulin sensitivity in contrast to other disease-related variables.

We are aware that this investigation has limitations. One of the main limitations is a small sample size, in turn reducing study power and increasing the likelihood of a Type II statistical error. That, and the heterogeneity of our population, may have contributed to our lack of statistical significance in the difference in insulin sensitivity between RA and matched controls. However, heterogeneity provided a valuable opportunity to determine predictors of insulin sensitivity in persons with RA. Nonetheless, we recognize that the predictive capability of the models presented is relatively modest. However, developing models as tools for predicting insulin sensitivity was not the study goal, but rather the objective was to determine the relative contribution of disease-related and traditional risk factors for insulin resistance in RA. Also, we believe this sample of persons with established and treated RA reflects what is seen in many rheumatology clinic cohorts, thus allowing generalizability of our findings regarding risks for insulin sensitivity in RA. One of the main strengths is using IVGTT to assess insulin sensitivity index in RA, thus emphasizing that stimulated tolerance tests allow a more complete assessment of insulin action.

Thus, in a population of patients with RA reflective of typical clinical cohorts, as compared to well-matched controls, insulin sensitivity index was not significantly lower in those with RA. Increased abdominal and thigh adiposity contributed to poorer insulin sensitivity but not disease activity or medication use. These findings imply that in established and treated RA, adipose depots, not disease-related factors, account for insulin sensitivity.

Acknowledgment

We thank the participants in this investigation as well as the Duke University Division of Rheumatology staff members who referred patients for this investigation. We appreciate helpful discussions with career award mentors, Drs. Gregory Samsa and Deborah Muoio, and assistance from the Department of Radiology (Dr. Rendon Nelson and Carolyn Lowery).

Footnotes

  • Supported by US National Institutes of Health/National Institute of Arthritis and Musculoskeletal and Skin Diseases K23AR054904, an American College of Rheumatology-Rheumatology Research Foundation (ACR-RRF)/Association for Specialty Professors (ASP) Junior Career Development Award in Geriatric Medicine funded by Atlantic Philanthropies, ACR-RRF, John A. Hartford Foundation and ASP, and an Early Career Development Award from the Central Society for Clinical Research.

  • Accepted for publication April 11, 2014.

REFERENCES

  1. 1.↵
    1. Maradit-Kremers H,
    2. Crowson CS,
    3. Nicola PJ,
    4. Ballman KV,
    5. Roger VL,
    6. Jacobsen SJ,
    7. et al.
    Increased unrecognized coronary heart disease and sudden deaths in rheumatoid arthritis: a population-based cohort study. Arthritis Rheum 2005;52:402–11.
    OpenUrlCrossRefPubMed
  2. 2.↵
    1. Dessein PH,
    2. Joffe BI,
    3. Stanwix AE
    . Editorial: should we evaluate insulin sensitivity in rheumatoid arthritis? Semin Arthritis Rheum 2005;35:5–7.
    OpenUrlCrossRefPubMed
  3. 3.↵
    1. Chung CP,
    2. Oeser A,
    3. Solus JF,
    4. Gebretsadik T,
    5. Shintani A,
    6. Avalos I,
    7. et al.
    Inflammation-associated insulin resistance: differential effects in rheumatoid arthritis and systemic lupus erythematosus define potential mechanisms. Arthritis Rheum 2008;58:2105–12.
    OpenUrlCrossRefPubMed
  4. 4.↵
    1. DeFronzo RA,
    2. Tripathy D
    . Skeletal muscle insulin resistance is the primary defect in type 2 diabetes. Diabetes Care 2009;32 Suppl 2:S157–63.
    OpenUrlFREE Full Text
  5. 5.↵
    1. Petersen KF,
    2. Dufour S,
    3. Savage DB,
    4. Bilz S,
    5. Solomon G,
    6. Yonemitsu S,
    7. et al.
    The role of skeletal muscle insulin resistance in the pathogenesis of the metabolic syndrome. Proc Natl Acad Sci U S A 2007;104:12587–94.
    OpenUrlAbstract/FREE Full Text
  6. 6.↵
    1. Hoes JN,
    2. van der Goes MC,
    3. van Raalte DH,
    4. van der Zijl NJ,
    5. den Uyl D,
    6. Lems WF,
    7. et al.
    Glucose tolerance, insulin sensitivity and beta-cell function in patients with rheumatoid arthritis treated with or without low-to-medium dose glucocorticoids. Ann Rheum Dis 2011;70:1887–94.
    OpenUrlAbstract/FREE Full Text
  7. 7.↵
    1. Penesova A,
    2. Radikova Z,
    3. Vlcek M,
    4. Kerlik J,
    5. Lukac J,
    6. Rovensky J,
    7. et al.
    Chronic inflammation and low-dose glucocorticoid effects on glucose metabolism in premenopausal females with rheumatoid arthritis free of conventional metabolic risk factors. Physiol Res 2013;62:75–83.
    OpenUrlPubMed
  8. 8.↵
    1. Svenson KL,
    2. Pollare T,
    3. Lithell H,
    4. Hallgren R
    . Impaired glucose handling in active rheumatoid arthritis: relationship to peripheral insulin resistance. Metabolism 1988;37:125–30.
    OpenUrlCrossRefPubMed
  9. 9.↵
    1. Hallgren R,
    2. Berne C
    . Glucose intolerance in patients with chronic inflammatory diseases is normalized by glucocorticoids. Acta Med Scand 1983;213:351–5.
    OpenUrlPubMed
  10. 10.↵
    1. Rosenvinge A,
    2. Krogh-Madsen R,
    3. Baslund B,
    4. Pedersen BK
    . Insulin resistance in patients with rheumatoid arthritis: effect of anti-TNFalpha therapy. Scand J Rheumatol 2007;36:91–6.
    OpenUrlCrossRefPubMed
  11. 11.↵
    1. Arnett FC,
    2. Edworthy SM,
    3. Bloch DA,
    4. McShane DJ,
    5. Fries JF,
    6. Cooper NS,
    7. et al.
    The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315–24.
    OpenUrlCrossRefPubMed
  12. 12.↵
    1. Bruce B,
    2. Fries JF
    . The Stanford Health Assessment Questionnaire: a review of its history, issues, progress, and documentation. J Rheumatol 2003;30:167–78.
    OpenUrlAbstract/FREE Full Text
  13. 13.↵
    1. Rigler SK,
    2. Studenski S,
    3. Wallace D,
    4. Reker DM,
    5. Duncan PW
    . Co-morbidity adjustment for functional outcomes in community-dwelling older adults. Clin Rehabil 2002;16:420–8.
    OpenUrlAbstract/FREE Full Text
  14. 14.↵
    1. Taylor-Piliae RE,
    2. Haskell WL,
    3. Iribarren C,
    4. Norton LC,
    5. Mahbouba MH,
    6. Fair JM,
    7. et al.
    Clinical utility of the Stanford brief activity survey in men and women with early-onset coronary artery disease. J Cardiopulm Rehabil Prev 2007;27:227–32.
    OpenUrlCrossRefPubMed
  15. 15.↵
    1. Prevoo ML,
    2. van ‘t Hof MA,
    3. Kuper HH,
    4. van Leeuwen MA,
    5. van de Putte LB,
    6. van Riel PL
    . Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995;38:44–8.
    OpenUrlCrossRefPubMed
  16. 16.↵
    1. Bergman RN,
    2. Ider YZ,
    3. Bowden CR,
    4. Cobelli C
    . Quantitative estimation of insulin sensitivity. Am J Physiol 1979;236:E667–77.
    OpenUrlPubMed
  17. 17.↵
    1. Irving BA,
    2. Weltman JY,
    3. Brock DW,
    4. Davis CK,
    5. Gaesser GA,
    6. Weltman A
    . NIH ImageJ and Slice-O-Matic computed tomography imaging software to quantify soft tissue. Obesity 2007;15:370–6.
    OpenUrlCrossRefPubMed
  18. 18.↵
    1. Ellis KJ
    . Human body composition: in vivo methods. Physiol Rev 2000;80:649–80.
    OpenUrlAbstract/FREE Full Text
  19. 19.↵
    1. Cohen J
    . Statistical power analysis for the behavioral sciences. Second ed. Hillsdale, NJ: Lawrence Erlbaum Associates Inc.; 1988.
  20. 20.↵
    1. Paolisso G,
    2. Valentini G,
    3. Giugliano D,
    4. Marrazzo G,
    5. Tirri R,
    6. Gallo M,
    7. et al.
    Evidence for peripheral impaired glucose handling in patients with connective tissue diseases. Metabolism 1991;40:902–7.
    OpenUrlCrossRefPubMed
  21. 21.↵
    1. Martin BC,
    2. Warram JH,
    3. Krolewski AS,
    4. Bergman RN,
    5. Soeldner JS,
    6. Kahn CR
    . Role of glucose and insulin resistance in development of type 2 diabetes mellitus: results of a 25-year follow-up study. Lancet 1992;340:925–9.
    OpenUrlCrossRefPubMed
  22. 22.↵
    1. Lorenzo C,
    2. Wagenknecht LE,
    3. Rewers MJ,
    4. Karter AJ,
    5. Bergman RN,
    6. Hanley AJ,
    7. et al.
    Disposition index, glucose effectiveness, and conversion to type 2 diabetes: the Insulin Resistance Atherosclerosis Study (IRAS). Diabetes Care 2010;33:2098–103.
    OpenUrlAbstract/FREE Full Text
  23. 23.↵
    1. Muoio DM,
    2. Neufer PD
    . Lipid-induced mitochondrial stress and insulin action in muscle. Cell Metab 2012;15:595–605.
    OpenUrlCrossRefPubMed
  24. 24.↵
    1. Romacho T,
    2. Elsen M,
    3. Rohrborn D,
    4. Eckel J
    . Adipose tissue and its role in organ crosstalk. Acta Physiol 2014;210:733–53.
    OpenUrlCrossRef
  25. 25.↵
    1. El-Kadre LJ,
    2. Tinoco AC
    . Interleukin-6 and obesity: the crosstalk between intestine, pancreas and liver. Curr Opin Clin Nutr Metab Care 2013;16:564–8.
    OpenUrlPubMed
PreviousNext
Back to top

In this issue

The Journal of Rheumatology
Vol. 41, Issue 10
1 Oct 2014
  • Table of Contents
  • Table of Contents (PDF)
  • Index by Author
  • Editorial Board (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word about The Journal of Rheumatology.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Adipose Depots, Not Disease-related Factors, Account for Skeletal Muscle Insulin Sensitivity in Established and Treated Rheumatoid Arthritis
(Your Name) has forwarded a page to you from The Journal of Rheumatology
(Your Name) thought you would like to see this page from the The Journal of Rheumatology web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Adipose Depots, Not Disease-related Factors, Account for Skeletal Muscle Insulin Sensitivity in Established and Treated Rheumatoid Arthritis
Hiba AbouAssi, K. Noelle Tune, Brian Gilmore, Lori A. Bateman, Gary McDaniel, Michael Muehlbauer, Janet L. Huebner, Helen M. Hoenig, Virginia B. Kraus, E. William St. Clair, William E. Kraus, Kim M. Huffman
The Journal of Rheumatology Oct 2014, 41 (10) 1974-1979; DOI: 10.3899/jrheum.140224

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

 Request Permissions

Share
Adipose Depots, Not Disease-related Factors, Account for Skeletal Muscle Insulin Sensitivity in Established and Treated Rheumatoid Arthritis
Hiba AbouAssi, K. Noelle Tune, Brian Gilmore, Lori A. Bateman, Gary McDaniel, Michael Muehlbauer, Janet L. Huebner, Helen M. Hoenig, Virginia B. Kraus, E. William St. Clair, William E. Kraus, Kim M. Huffman
The Journal of Rheumatology Oct 2014, 41 (10) 1974-1979; DOI: 10.3899/jrheum.140224
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
    • Abstract
    • MATERIALS AND METHODS
    • RESULTS
    • DISCUSSION
    • Acknowledgment
    • Footnotes
    • REFERENCES
  • Figures & Data
  • References
  • Info & Metrics
  • PDF
  • eLetters

Keywords

SKELETAL MUSCLE
INSULIN RESISTANCE
PHYSICAL ACTIVITY
BODY COMPOSITION

Related Articles

Cited By...

More in this TOC Section

  • Incidence Rates of Psoriasis in Children With Inflammatory Bowel Disease and Juvenile Arthritis Treated With Tumor Necrosis Factor Inhibitors and Disease-Modifying Antirheumatic Drugs
  • COVID-19 vaccine uptake among patients with systemic lupus erythematosus in the American Midwest: The Lupus Midwest Network (LUMEN)
  • Association of M2 Macrophages, Th2, and B Cells With Pathomechanism in Microscopic Polyangiitis Complicated by Interstitial Lung Disease
Show more Article

Similar Articles

Keywords

  • SKELETAL MUSCLE
  • insulin resistance
  • physical activity
  • body composition

Content

  • First Release
  • Current
  • Archives
  • Collections
  • Audiovisual Rheum
  • COVID-19 and Rheumatology

Resources

  • Guide for Authors
  • Submit Manuscript
  • Author Payment
  • Reviewers
  • Advertisers
  • Classified Ads
  • Reprints and Translations
  • Permissions
  • Meetings
  • FAQ
  • Policies

Subscribers

  • Subscription Information
  • Purchase Subscription
  • Your Account
  • Terms and Conditions

More

  • About Us
  • Contact Us
  • My Alerts
  • My Folders
  • Privacy/GDPR Policy
  • RSS Feeds
The Journal of Rheumatology
The content of this site is intended for health care professionals.
Copyright © 2022 by The Journal of Rheumatology Publishing Co. Ltd.
Print ISSN: 0315-162X; Online ISSN: 1499-2752
Powered by HighWire